Aims: The main purpose of this first atomoxetine study in Japanese adults with Attention-Deficit/Hyperactivity Disorder (ADHD) was to investigate the tolerability of an 8 week treatment regimen.
INTRODUCTION
Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder with onset typically prior to 7 years of age. The predominant symptoms involve problems of inattention, hyperactivity and impulsivity. ADHD had been thought to be a specific disorder of children, and therefore was not considered to be observed in adults for a long time. 1 However, multiple lines of research have demonstrated that ADHD is a chronic disorder with onset in childhood that persists into adulthood in 30 to 80% of all children with ADHD. 2, 3, 4 Awareness of adult ADHD was low, and ADHD symptoms in adulthood include poor planning and organization, poor memory, difficulty in finishing daily jobs, lower academic achievement, distractibility and restlessness. 5, 6 Accordingly, some adult patients find it difficult to cope in their work and life. In addition, ADHD is known to be associated with various comorbid disorders. 7 Although psycostimulants and atomoxetine are available for adult ADHD patients in some other countries, there is no approved medication for Japanese adult patients. 8 Therefore, medication in adults is considered necessary for treatment of ADHD symptoms. 5 Atomoxetine hydrochloride (hereafter referred to as atomoxetine) is a selective inhibitor of the presynaptic norepinephrine transporter, with little affinity for other neurotransmitter transporters or receptors. 9 Atomoxetine is classified as a non-stimulant and has a very low risk of abuse. 10 Atomoxetine is known to be metabolized by cytochrome P450 2D6 (CYP2D6) predominantly. 11, 12 It is reported that few people are classified as poor metabolizers (PM), that is some CYP2D6 gene mutations or deletions associated with defective CYP2D6 metabolism. Shimizu et al reported that
there was racial differences in the frequency of PM on CYP2D6; 1.9% of Asian and 7.7% of Caucasians. 13 In a placebo-controlled, double-blind trial of atomoxetine in Japanese children and adolescents with ADHD aged from 6 to 17 years, atomoxetine was shown to be generally well tolerated with no safety concerns. 14 Atomoxetine was also found in that study to be effective at reducing ADHD symptoms as shown by decreases in ADHD RS-IV-J:I total score (Attention-Deficit/Hyperactivity
Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored, translated and validated in Japanese). As of February 2009, atomoxetine has been approved for children and adolescents with ADHD in 84 countries and regions.
While there are a number of studies of atmoxetine treatment in child and adolescent ADHD patients, few studies have been reported in adult ADHD patients. However, these studies have also demonstrated that atomoxetine was safe and efficacious in adults with ADHD 15, 16 and at present atomoxetine has been approved for adult use in more than 39 countries including the United
States. On the other hand, currently there are no data available regarding the safety and efficacy of atomoxetine in Asian adult patients with ADHD.
As a first step in this patient group, the present study investigated the tolerability of atomoxetine in Japanese adults with ADHD to obtain a preliminary assessment of safety in these patients. In addition, changes in ADHD symptoms following atomoxetine treatment were assessed by using the Japanese version of the Conners' Adult ADHD Rating Scale-Investigator Rated:
Screening Version (CAARS-Inv:SV-J; Multi-Health System Inc, North Tonawanda , NY, U.S.A.).
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METHODS
Patients
This study included 45 Japanese adult ADHD patients aged 18.5 to 59.4 years from 8 the CAARS Inv:SV-J was validated by evaluating internal consistency, the capability of distinguishing between ADHD patients and healthy adults, and the correlation with other rating scales. Patients who met the following DSM-IV™ diagnostic criteria were excluded from the study: current major depressive disorder, current anxiety disorder requiring antianxiety drug therapy except for those taking benzodiazepines analogues, either alcohol dependence or alcohol abuse, or either drug dependence or drug abuse.
Patients with organic brain disease, or a history of bipolar disorder, schizophrenia, psychotic disorder or pervasive developmental disorder (DSM-IV™) were also excluded. 9 All patients underwent full clinical and laboratory screening; information on patient medical and psychiatric history was collected, and all previous therapy for ADHD was noted. Additionally, blood samples were drawn at the initial study visit and analyzed for CYP2D6 genotype to categorize patients into extensive metabolizers (EM) or poor metabolizers (PM). If patients had two nonfunctional alleles, a PM genotype was assigned; otherwise, an EM genotype was assigned.
Written informed consent was obtained from each participant prior to beginning the procedures for this study. Each site's institutional review board approved the conduct of the study, which was developed in accordance with good clinical practice (GCP) and the ethical principles in Declaration of Helsinki.
Study Design
This was an open-label, dose escalation study that consisted of 3 study periods ( Figure 1 ). Study Period I was an assessment and washout period to collect baseline measures prior to administration of atomoxetine. If it was determined at Visit 1 that the patient was taking an excluded drug, this drug was discontinued and a washout period conducted before giving atomoxetine to the patient at Visit 2. Study Period II was an 8 week, dose escalation atomoxetine treatment period. Patients started once daily oral administration of atomoxetine at 40 mg/day for 7 days. This was followed 10 by stepwise titration to a maximum of 120 mg/day （Figure 1） unless there was a tolerability issue. However, if the investigator determined there was a safety concern and it was difficult to increase or maintain the dose, the dose was either maintained at the current level or reduced to the next lowest level, respectively. Study Period II was followed by a 2-week observational period after study drug withdrawal (Study Period III).
Tolerability and Safety
The primary objective of this study was to assess tolerability, as measured by the discontinuation rate due to adverse events, in doses up to 120 mg/day. An adverse event was defined as any unfavorable medical event, newly emerged or the deterioration of a preexisting condition, that occurred in a patient after administration of atomoxetine, without regard to the possibility of a causal relationship. Adverse events, laboratory tests, vital signs, weight and electrocardiograms (ECG) were collected in Study Periods II and III. For analysis of ECG results, the Fridericia corrected QT interval (QTcF) was preferred because the Bazett method of correction is known to over-correct heart rate effects, and is therefore not appropriate when assessing safety in a drug that increases heart rate.
ADHD Symptoms and other Efficacy Measures
ADHD symptoms were assessed by using the 18 items of CAARS-Inv:SV-J scale, the Japanese version of the Conners' Adult ADHD Rating Scale-Investigator Rated:
Screening Version. 17 This scale contains two 9 item symptom-related subscales:
inattention and hyperactivity-impulsivity. The investigators met with patients at biweekly study visits to discuss their symptoms during the previous week and evaluated each CAARS-Inv:SV-J item using a 4-point scale. The change from baseline to endpoint in the 18 item total ADHD symptom score (sum of the inattention and hyperactivity/impulsivity subscales) was used to measure changes in ADHD symptoms. The mean change from baseline to endpoint in the inattention and hyperactivity/impulsivity subscales was also assessed. Severity of ADHD was further evaluated using the CGI-ADHD-S score based on a 7 item scale. 19, 20 In addition, CAARS-S:SV-J total ADHD symptoms score (self-check), Hamilton To summarize the data, descriptive statistics were used for continuous variables.
Both frequency counts and percentages were used for categorical variables. All statistical tests were performed based on a two-sided significance level of 0.05 unless otherwise specified.
Adverse events and vital sign values were summarized with frequency and percentage. Terms for adverse events were coded by MedDRA version 11.0. The discontinuation rate due to adverse events was summarized using the frequency, (23/45) of patients were markedly ill, and all patients were at least moderately ill in terms of ADHD severity.
The proportion of compliant patients at each visit was between 93.2% and 100.0%.
Compliance was defined as having taken atomoxetine on at least 70% of the days between one visit and the next. At Visit 5, when according to the protocol the patient was able to be prescribed the maximum dose of 120 mg/day, the mean dose was close to the maximum (Visit 5: 113.0 mg/day and Visit 6: 113.8 mg/day; median 120.0 mg/day at both visits). In addition, the proportion of patients taking the maximum dose at Visits 5 and 6 was high (78.0% and 75.0%, respectively).
Discontinuation rate due to adverse events
The tolerability of atomoxetine was assessed by the discontinuation rate due to adverse events. Three patients discontinued at Visit 4 (Study Period II) due to adverse events resulting in an overall discontinuation rate of 6.7% (3/45 15 [95% CI = 1.4-18.3]). Adverse events that led to discontinuation were nausea, malaise and anorexia (1 patient each), all of which were considered by the investigator to be possibly related to atomoxetine. At the time of these events, atomoxetine doses were between 80 mg/day and 105 mg/day. No patients discontinued due to an adverse event while on a dose of 120 mg/day. Fourteen (31.1%) patients did not progress to a higher dose of study drug at the prescribed time due to adverse events. Nausea and malaise were the two most commonly reported events that prevented an increase in dose or led to a dose reduction. and thirst (20.0%). While one patient experienced severe anorexia which led to discontinuation from the study, all other adverse events were mild or moderate.
Adverse events
During Study Period III, the most frequently occurring adverse event was headache (24.4%); all adverse events were mild or moderate.
Laboratory tests, vital signs, weights and ECGs
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Statistically significant mean decreases were seen for alanine aminotransferase Changes in mean weight from baseline at each visit were statistically significant (p<0.001). Mean weight decreased from baseline to endpoint (LOCF) by 1.6 kg.
A statistically significant increase in mean QT interval from baseline to endpoint (LOCF) was observed using the Bazett correction (12.8 ms: p<0.001), however, no statistically significant change was seen in the preferred QTcF interval (2.1 msec :
p=0.349). While four patients had a QTcF interval increase of more than 30 msec from baseline in Study Period II, no patients showed an increase from baseline of more than 60 msec.
ADHD Symptoms and other Efficacy Measures
A statistically significant (p<0.001) decrease of -15.0 from baseline to endpoint (LOCF) was observed in the mean CAARS-Inv:SV-J total ADHD symptom score 
DISCUSSION
The present study is the first investigation of the tolerability of atomoxetine in Japanese adult ADHD patients. The results suggested that atomoxetine was well tolerated and suggested that it would be safe in these patients. Furthermore, a decrease in CAARS-Inv:SV-J scores was observed following administration of atomoxetine.
Of the 45 patients enrolled in this study, 39 patients completed Study Period II with 8 weeks of atomoxetine treatment. The discontinuation rate due to adverse events was 6.7%. This was almost similar to the rates, 7.8 % and 9.3 %, observed in two large-scale, placebo-controlled studies completed in the U.S. in adult ADHD patients. 15 In addition, the proportion of compliant patients at each visit was more than 93.2%. These results suggest that treatment with atomoxetine was well tolerated in Japanese adults with ADHD.
There were no unexpected adverse events observed in these Japanese patients.
The most commonly reported adverse events were nausea, headache, anorexia and somnolence, all of which have been reported in previous overseas studies with atomoxetine. 15, 21, 22 Statistically significant changes were seen in some laboratory tests, vital signs and ECGs, however, these changes were small and were not considered clinically significant. The increase in heart rate, significant changes in diastolic blood pressure were not unexpected from pharmacologic action of atomoxetine. The Fridericia correction of the QT interval (QTcF) was the preferred method of assessment, and no statistical significance was observed in the mean change from baseline to endpoint in QTcF interval. Michelson et al. reported that no serious safety concerns were observed during a 10-week treatment period in two placebo-controlled, double-blind studies with adult ADHD patients in the U.S., while modest mean increases in blood pressures and heart rate appeared to be associated with atomoxetine. 15 These results suggested that the Japanese adult ADHD patients in this study had a similar safety profile to that seen in US studies with adult ADHD patients. However, further study will be required to investigate tolerability and safety more thoroughly because of the small size and open-label design of this study.
A proportion of PM patients was 2.2% (1/45) in our study. Shimizu et al reported that racial differences in the frequency of PM on CYP2D6 was 1.9% of Asian and 7.7% of Caucasians. 13 From these results, PM frequency in Japanese patients in our study was almost consistent with the previous report and was not unexpected, although number of patients in our study was small and there is a limitation to interpret this data.
Atomoxetine has been approved for the treatment of children and adolescents with ADHD in Japan in April 2009. In a placebo-controlled, double-blind study in 245
Japanese children and adolescents with ADHD, two patients in the atomoxetine treatment groups discontinued from the study due to adverse events. Importantly, adverse events reported at least 5% of patients were nasopharyngitis, headache, decreased appetite, somnolence and nausea, vomiting, abdominal pain and diarrhea 14 . There were no major differences in the safety profiles between the Japanese adult ADHD patients in this study and Japanese pediatric ADHD patients reported in the previous study.
This study also took a preliminary look at how ADHD symptoms changed in these patients during a course of atomoxetine administration. Symptoms were evaluated by using a Japanese version (CAARS-SV-J) of the Conners Adult ADHD Rating ScaleScreening Version (CAARS-SV). Treatment with atomoxetine for 8 weeks showed statistically significant decreases in CAARS-Inv:SV-J total ADHD symptoms scores in a time-dependent manner from baseline to the last observational visits. This result was similar to previous studies showing that atomxetine improved ADHD symptoms in adults as measured by CAARS-Inv:SV-J total score. 15, 20 . Although further study to evaluate ADHD symptoms in Japanese adults will be required, these results suggest that atomoxetine would be expected to be efficacious and safe in Japanese adults with ADHD as has been shown in other countries.
Limitations treatment period, the results of efficacy and safety in this study was suggestive for treatment with atomoxetine in Japanese adult patients, however, we can not conclude definitely, Therefore, safety and efficacy need to be confirmed in a larger scale, placebo-controlled study in Japanese adult patients with ADHD. Such a study, along with a long term treatment study, is now being conducted to achieve these objectives.
CONCLUSION
This first Asian open-label study with 45 Japanese adults with ADHD showed that treatment with atomoxetine for 8 weeks was well tolerated in these patients. The most commonly reported adverse events were nausea, nasopharyngitis, headache , somnolence, anorexia and thirst, and most of these events were mild or moderate.
The results of this study suggest that atomoxetine would be expected to be efficacious and safe in Japanese adults with ADHD, although a placebo-controlled study will be required for further demonstration.. 
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